Please login to the form below
Remdesivir
This page shows the latest Remdesivir news and features for those working in and with pharma, biotech and healthcare.
US regulators set to approve oral antiviral against COVID-19
Oral medications like molnupiravir and Paxlovid are significantly more convenient than the injectable COVID-19 treatments that are currently being used, including Gilead’s Veklury (remdesivir).
Latest news
-
Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug
This includes Gilead’s remdesivir, although the drug is not available for oral administration and was also not recommended in the World Health Organization’s (WHO) COVID-19 drug scheme last
-
Gilead reveals real-world data for COVID-19 drug Veklury
Veklury (remdesivir) has been approved for emergency use in adult and paediatric patients, aged 12 years and older and weighing at least 40kg, who have been hospitalised with COVID-19 in
-
US announces $3bn funding boost for antiviral COVID-19 treatments
This includes Gilead’s remdesivir, although the drug is not available for oral administration and was also not recommended in the World Health Organization’s (WHO) COVID-19 drug scheme last
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
The total revenues for Q1 increased by 16% to a total of $6.4bn compared to the same period last year, with Gilead attributing much of that growth to Veklury (remdesivir),
-
GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
While we are disappointed with the recommendation of the DSMB, we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir
More from news
Approximately 12 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
The search for effective drug treatments for COVID-19
Trials) evaluating five-day and ten-day dosing durations of remdesivir in patients with severe disease. ... remdesivir”. Can you offer more details about the studies published in the aforementioned peer-reviewed journals?
-
Working together against COVID-19
Gilead shared some positive updates on social media about remdesivir but did not address all HCP concerns. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.
-
COVID-19: the race to find a vaccine
A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... Yet, it is unlikely that any of the drugs will be a panacea, with Jefferies analysts saying remdesivir “might be modestly helpful”.
-
As COVID-19 takes over the world, biopharma fights back
An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... Lane is currently overseeing ongoing studies at the US National Institutes of
More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Live Webinar: Gamifying Surgical Training to Improve Patient Outcomes
- First trial of a vaccine against Alzheimer’s launches
- AZ appoints Susan Galbraith as executive vice president, oncology R&D
- Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
- MHRA approves second COVID-19 antibody treatment
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
